HMGB1 and thrombin mediate the blood-brain barrier dysfunction acting as biomarkers of neuroinflammation and progression to neurodegeneration in Alzheimer’s disease - Festoff, Barry W.; Sajja, Ravi K.; van Dreden, Patrick; Cucullo, Luca (Journal of neuroinflammation, 2016)
Keywords: Aged; Aged, 80 and over; Alzheimer Disease - complications; Alzheimer's disease; Amyloid beta-Peptides - blood; Analysis; Antibodies - pharmacology; Biological markers; Blood-brain barrier; Blood-Brain Barrier - drug effects; Blood-Brain Barrier - metabolism; Blood-Brain Barrier - physiopathology; Capillary Permeability - physiology; Care and treatment; Cells, Cultured; Cognitive Dysfunction - complications; Complications and side effects; Development and progression; Disease Progression; Encephalitis - etiology; Encephalitis - pathology; Endothelial Cells - metabolism; Female; Glycation End Products, Advanced - blood; HMGB1 Protein - immunology; HMGB1 Protein - metabolism; HMGB1 Protein - pharmacology; Humans; Male; Middle Aged; Nerve Degeneration - etiology; Nerve Degeneration - pathology; Peptide Fragments - blood; Thrombin - metabolism; Blood-brain barrier; Neurodegeneration; Biomarkers; Clinical; Neuroinflammation; Thrombin; HMGB1; Permeability; DAMPS